Kailera Therapeutics (KLRA)
Develops injectable and oral obesity medicines outside Greater China under a Hengrui license.
Something off on this page? Send us feedback.
Develops injectable and oral obesity candidates, including ribupatide, KAI-7535, and KAI-4729. The pre-commercial business holds rights outside Greater China to Hengrui-originated programs and relies on Hengrui's prior development data.
Clinical development centers on injectable and oral obesity candidates: ribupatide, oral ribupatide, KAI-7535, and KAI-4729. Ribupatide is a GLP-1/GIP dual agonist, KAI-7535 an oral small-molecule GLP-1 receptor agonist, and KAI-4729 an injectable GLP-1/GIP/glucagon tri-agonist. The company has initiated global obesity trials, including a late-stage clinical program for ribupatide injection.
Rights cover development, manufacturing, and commercialization outside China, Hong Kong, Macau, and Taiwan, while Hengrui retains responsibility in Greater China. The pre-commercial model relies on Hengrui's prior nonclinical and clinical work and on completing further development and commercialization outside Greater China.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $916.7M · Total debt $10.2M · Total assets $1.21B · Shareholders' equity $1.12B
- Revenue
- $0
- Operating income
- −$121.4M
- Net income
- −$111.3M
No dividends on record.
| Institutions101 holders · as of Jun 30, 2026 | 89.78% | 116.39M shares | |
| Insiders1 holder · as of Jun 11, 2026 | 0.03% | 38.1K shares | |
| Strategic holders1 holder · as of Aug 5, 2026 | 8.88% | 11.51M shares | |
| Otherremainder | 1.31% | 1.70M shares |
129.64M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Bain Capital Investors LLCInstitution | 20.25% | 26.26M | 13Fas of Jun 30, 2026 |
BCPE Perseus Investor, LPInstitution | 20.25% | 26.26M | 13Dfiled Apr 23, 2026 ↗ |
BCLS Fund IV Investments, L.P.Institution | 17.42% | 22.58M | 13Dfiled Apr 23, 2026 ↗ |
Bain Capital Life Sciences Investors, LLCInstitution | 17.42% | 22.58M | 13Fas of Jun 30, 2026 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd.1Strategic10 percent owner | 8.88% | 11.51M | 13Gfiled Aug 5, 2026 ↗ |
| See all 25 → | |||
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s transaction reports restate only vehicles that traded; the 2026 ownership statement (11.51M) is used instead.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 20, 2026 | RTW Investments, LP | 10 percent owner | +500,000 | $16.00 |
| Apr 20, 2026 | Andrew T. Kaplan | director, 10 percent owner: | +8,398,438 | $16.00 |
| Apr 20, 2026 | Bain Capital Life Sciences Investors, LLC | 10 percent owner | +1,562,500 | $16.00 |
| Apr 20, 2026 | Adam Koppel | director, 10 percent owner: | +1,562,500 | $16.00 |
| Apr 20, 2026 | Bain Capital Investors LLC | 10 percent owner | +8,398,438 | $16.00 |
- Eli Lilly
Marketed dual incretin therapy and oral and triple-agonist pipeline
- Novo Nordisk (ADR)
Marketed GLP-1 obesity medicines and next-generation programs
- Amgen
Phase 3 incretin weight-management program with less-frequent dosing
- Viking Therapeutics
Dual GLP-1/GIP candidate in injectable and oral obesity programs
- AstraZeneca (ADR)
Oral GLP-1 and multi-agonist programs for obesity
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Kailera Therapeutics | $16.20 | +2.27% | $2.05B | — | — | — | — |
| Eli Lilly | $1,165.66 | +0.54% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Novo Nordisk (ADR) | $47.42 | +1.42% | $207.69B | 11.5 | 18.9 | 4.1 | +0.0% |
| Amgen | $442.00 | −0.19% | $239.00B | 27.5 | 18.9 | 6.3 | +9.7% |
| Viking Therapeutics | $32.98 | −1.55% | $3.91B | — | — | — | — |
| AstraZeneca (ADR) | $163.77 | +1.31% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Median | 25.9 | 18.9 | 5.2 | +8.0% |